Lipid Nanoparticles
Lipid nanoparticles with specific DODAP and DOPE ratios provide spleen-specific gene delivery, addressing the need for targeted gene expression in organs like the spleen for effective immunotherapy and gene therapy.
Patent Information
- Application Number
- JP2021526847
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-24
- Filing Date
- 2020-06-17
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-06-17
AI Technical Summary
There is a lack of gene delivery carriers that can selectively target and achieve high gene expression in organs other than the liver, which is crucial for realizing systemically administered gene therapy, particularly in organs like the spleen that are important for immunotherapy and gene therapy.
Lipid nanoparticles composed of specific ratios of 1,2-dioleoyl-3-dimethylaminopropane (DODAP) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) are developed, with optional inclusion of sterols and polyalkylene glycol-modified lipids, to enhance spleen-specific gene expression.
The lipid nanoparticles exhibit high gene expression activity in the spleen, making them effective carriers for immunotherapy and gene therapy by selectively delivering genes to spleen cells.
Smart Images

Figure 0007589998000014 
Figure 0007589998000015 
Figure 0007589998000016
Abstract
Citation Information
Patent Citations
Agent for imparting ph dependant cationic property to lipid membrane structure, the lipid membrane structure given the ph dependant cationic property thereby, and production method for lipid membrane structure
JP2013245190A
Lipid nanoparticle compositions and methods for mRNA delivery
JP2014523411A
Lipid constructs for targeting to vascular smooth muscle tissue
US5660855A
Lipid membrane structure for delivery into sirna cell
WO2018230710A1
